Intermediate hepatocellular carcinoma (BCLC B)
Intermediate hepatocellular carcinoma is several tumours inside a working liver, too many to cut out but with no spread beyond it. The standard treatment for two decades has been chemoembolisation through the hepatic artery, and trials now show that adding immunotherapy and anti-angiogenic drugs to it delays progression.
Overview
BCLC stage B covers multinodular hepatocellular carcinoma with preserved liver function, no cancer-related symptoms and no macrovascular invasion or extrahepatic spread. The 2022 BCLC update split it into three groups: patients whose tumour burden allows downstaging or extended transplant criteria, those with well-defined nodules suited to transarterial chemoembolisation, and those with diffuse, infiltrative or bilobar disease who do better moving straight to systemic therapy, a change described as treatment stage migration.
Transarterial chemoembolisation delivers chemotherapy-loaded particles or drug-eluting beads into the arteries feeding the tumours and blocks them; two randomised trials in 2002 (Llovet in Barcelona and Lo in Hong Kong) showed it prolongs survival, and it has been the standard since. Radioembolisation with yttrium-90 microspheres is an alternative with fewer post-procedure symptoms, though phase 3 trials against sorafenib in more advanced disease were negative. Repeated embolisation damages the liver, so the ART and other scores guide when to stop and switch.
Two phase 3 trials published in the Lancet in 2025 added systemic therapy to chemoembolisation: EMERALD-1 combined durvalumab and bevacizumab with TACE and extended median progression-free survival from 8.2 to 15.0 months, and LEAP-012 combined lenvatinib and pembrolizumab with TACE and extended it from 10.0 to 14.6 months; overall survival was immature in both at first analysis. EMERALD-3, testing durvalumab and tremelimumab with TACE, reported a benefit in 2026. The atezolizumab-bevacizumab and other advanced-stage regimens are also used directly in patients with high tumour burden, and ongoing trials compare systemic therapy alone with the combinations.
State of the art
- Chemoembolisation remains the backbone, but the 2022 BCLC update sends patients with diffuse or high-burden disease straight to systemic therapy.
- EMERALD-1 and LEAP-012 are the first phase 3 trials to improve on TACE alone in twenty years.
- Whether the combinations lengthen life, not just time to progression, is still awaited.
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowHypophysitis or adrenal crisis
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
- Emergency services nowBowel perforation
Sudden severe abdominal pain, a hard or very tender abdomen, or abdominal pain with vomiting and fever. Boxed warning for gastrointestinal perforation on bevacizumab.
- Emergency services nowFainting or palpitations
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
- Check before combiningFood and drink: Pembrolizumab
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
- Check before combiningHeart rhythm (QT): Lenvatinib
Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
- Check before combiningKidneys: Lenvatinib
Reduce in severe renal impairment.
See all on the product pages:AtezolizumabBevacizumabDurvalumabLenvatinibPembrolizumabTremelimumab·Printable cards in the navigator
Anatomy and lymph node drainage
- Right lobe (segments V-VIII)
- Left lobe (segments II-IV)
- Portal vein (macrovascular invasion)
- Capsule and diaphragm surface
- Nodes: hepatic hilar
- Nodes: coeliac
- Nodes: paracaval
Hepatocellular carcinoma grows in a cirrhotic liver and spreads first inside it and into the portal vein, so staging depends on liver function and vascular invasion as much as on size.
- Right lobe (segments V-VIII)Multinodular HCC in a cirrhotic liver within the up-to-seven criteria (downstaging or extended transplant)
- Left lobe (segments II-IV)
- Portal vein (macrovascular invasion)
- Capsule and diaphragm surface
- hepatic hilar
- coeliac
- paracaval
Same organ: Hepatocellular carcinoma, Early hepatocellular carcinoma (BCLC 0 and A), Advanced hepatocellular carcinoma (BCLC C), Hepatoblastoma
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Multiple tumours confined to a liver that still functions, without vein invasion or spread; the most heterogeneous BCLC stage, for which the 2022 update expects a median survival above two and a half years with chemoembolisation and now systemic therapy.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Transarterial chemoembolisation, conventional or with drug-eluting beads, repeated on demand; radioembolisation as an alternative.
Durvalumab with bevacizumab (EMERALD-1) or lenvatinib with pembrolizumab (LEAP-012) added to TACE, where approved; durvalumab-tremelimumab with TACE after EMERALD-3.
Systemic therapy as for advanced disease (atezolizumab-bevacizumab or durvalumab-tremelimumab) instead of embolisation.
Chemoembolisation or radioembolisation as a bridge, then liver transplantation.
Subtypes & biomarkers
top- Multinodular HCC in a cirrhotic liver within the up-to-seven criteria (downstaging or extended transplant)
- Well-defined nodules suitable for TACE
- Diffuse or infiltrative bilobar HCC (systemic therapy first)
- TACE-refractory HCC
- BCLC B treated with TACE plus systemic therapy (EMERALD-1, LEAP-012)
- Tumour number and size (up-to-seven and other burden criteria)
- Child-Pugh and ALBI liver function before and after each embolisation
- Alpha-fetoprotein response
- Modified RECIST response on contrast imaging
- Absence of macrovascular invasion and extrahepatic spread (defines the stage)
How often this target appears
- 2002Llovet and Lo randomised trials: chemoembolisation prolongs survival
- 2010Drug-eluting bead TACE (PRECISION V) matches conventional TACE with less toxicity
- 2022BCLC update subdivides intermediate stage and introduces treatment stage migration
- 2025EMERALD-1 and LEAP-012: systemic therapy plus TACE delays progression
- 2026EMERALD-3: durvalumab-tremelimumab plus TACE reported positive
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 11 changes by month →- 2026-09-17This recordIntermediate hepatocellular carcinoma (BCLC B)Facts on this page last checked
When this page itself was last checked or edited.
- 2026Trial resultEMERALD-3EMERALD-3 reported
PFS HR ~0.
- 2026MilestoneEMERALD-3EMERALD-3: durvalumab-tremelimumab plus TACE reported positive
A milestone in how this cancer is treated.
- 2025MilestoneEMERALD-1EMERALD-1 and LEAP-012: systemic therapy plus TACE delays progression
A milestone in how this cancer is treated.
- 2024Trial resultEMERALD-1EMERALD-1 reported
PFS HR 0.
- 2024Trial resultLEAP-012LEAP-012 reported
PFS HR 0.
What is in development for Intermediate hepatocellular carcinoma (BCLC B), drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Technologies being tested · 1
Trials reported · 3
Combinations being explored · 1
Open problems and what is being done
No overall survival gain yet shown for TACE combinations.
Which patients should skip embolisation and go straight to systemic therapy.
Liver damage from repeated embolisation limits later treatment options.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Expert centres
topExpert centres
Seoul · hospital | South Korea | none recorded | 0 | 1,177 | 18,820 | none recorded | #4 |
Rochester, MN · hospital | United States | 0 | 4,511 | 44,748 | #5 | ||
Baltimore · cancer center | United States | 0 | 2,955 | 41,449 | #10 | ||
Rozzano (Milan) · hospital | Italy | none recorded | 0 | 1,031 | 10,720 | - | |
Madrid · hospital | Spain | none recorded | 0 | 764 | 13,767 | - | |
Taipei · hospital | Taiwan | none recorded | 0 | 746 | 8,966 | - | |
Lausanne · hospital | Switzerland | none recorded | 0 | 509 | 9,176 | - | |
Brussels · cancer center | Belgium | none recorded | 0 | 489 | 8,689 | - | |
Philadelphia, PA · consortium | United States | none recorded | 0 | 165 | 1,237 | - | |
Neu-Isenburg · consortium | Germany | none recorded | 0 | 94 | 1,947 | none recorded | - |
Bern · consortium | Switzerland | none recorded | 0 | 82 | 2,450 | - | |
Chicago, IL · consortium | United States | none recorded | 0 | 42 | 482 | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Intermediate hepatocellular carcinoma but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about Intermediate hepatocellular carcinoma
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Tumour number and size, Child-Pugh and ALBI liver function before and after each embolisation, Alpha-fetoprotein response, Modified RECIST response on contrast imaging, Absence of macrovascular invasion and extrahepatic spread), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Multinodular HCC in a cirrhotic liver within the up-to-seven criteria, Well-defined nodules suitable for TACE, Diffuse or infiltrative bilobar HCC.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Well-defined nodules, preserved liver function
- For my situation (well-defined nodules, preserved liver function), which of the standard options do you recommend and why?Why: Guideline options include: Transarterial chemoembolisation, conventional or with drug-eluting beads, repeated on demand; radioembolisation as an alternative.
TACE plus systemic therapy
- For my situation (tace plus systemic therapy), which of the standard options do you recommend and why?Why: Guideline options include: Durvalumab with bevacizumab (EMERALD-1) or lenvatinib with pembrolizumab (LEAP-012) added to TACE, where approved; durvalumab-tremelimumab with TACE after EMERALD-3.
- Am I a candidate for Durvalumab, Bevacizumab, Lenvatinib or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EMERALD-1 and LEAP-012 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
High burden or diffuse disease
- For my situation (high burden or diffuse disease), which of the standard options do you recommend and why?Why: Guideline options include: Systemic therapy as for advanced disease (atezolizumab-bevacizumab or durvalumab-tremelimumab) instead of embolisation.
- Am I a candidate for Atezolizumab, Bevacizumab, Durvalumab or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of IMbrave150 and HIMALAYA apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Within transplant criteria after downstaging
- For my situation (within transplant criteria after downstaging), which of the standard options do you recommend and why?Why: Guideline options include: Chemoembolisation or radioembolisation as a bridge, then liver transplantation.
Any stage
- Are there clinical trials I could join, for example of EMERALD-3, TACE + immunotherapy/anti-VEGF, Radioembolisation (TARE / SIRT, yttrium-90), Durvalumab?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “No overall survival gain yet shown for TACE combinations”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Which patients should skip embolisation and go straight to systemic therapy”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Newly diagnosed? Read the first 60 days with Intermediate hepatocellular carcinoma, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
9targets
7drugs
6companies
6terms
3trials
5pairings
1Latest papers
topQuery for this cancer: (TITLE:"Intermediate hepatocellular carcinoma" OR ABSTRACT:"Intermediate hepatocellular carcinoma" OR TITLE:"BCLC B" OR ABSTRACT:"BCLC B" OR TITLE:"Intermediate-stage HCC" OR ABSTRACT:"Intermediate-stage HCC" OR TITLE:"Multinodular HCC" OR ABSTRACT:"Multinodular HCC" OR TITLE:"TACE-eligible hepatocellular carcinoma" OR ABSTRACT:"TACE-eligible hepatocellular carcinoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Intermediate hepatocellular carcinoma (BCLC B), not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerEarly hepatocellular carcinoma (BCLC 0 and A)
Shares Bridging therapy, BCLC staging, Liver transplantation for cancer (Milan criteria and beyond), Radioembolisation (TARE / SIRT, yttrium-90) and the tag subtype-page.
- CancerAdvanced hepatocellular carcinoma (BCLC C)
Shares HIMALAYA, IMbrave150, Radioembolisation (TARE / SIRT, yttrium-90), Tremelimumab and the tag subtype-page.
- CancerMicrosatellite-unstable (MSI-high) gastric cancer
Shares Tremelimumab, Durvalumab, Pembrolizumab and the tag subtype-page.
- CancerIntrahepatic cholangiocarcinoma
Shares Liver transplantation for cancer (Milan criteria and beyond), Radioembolisation (TARE / SIRT, yttrium-90), Durvalumab, Pembrolizumab and the tag subtype-page.
- CancerExtrahepatic cholangiocarcinoma (perihilar and distal)
Shares Liver transplantation for cancer (Milan criteria and beyond), Durvalumab, Pembrolizumab and the tag subtype-page.
- CancerAnaplastic thyroid cancer
Shares Lenvatinib, Pembrolizumab and the tag subtype-page.
- CancerClear cell renal cell carcinoma
Shares Lenvatinib, Pembrolizumab and the tag subtype-page.
- CancerMuscle-invasive and advanced bladder cancer
Shares Durvalumab, Pembrolizumab and the tag subtype-page.